{"id":"NCT02227446","sponsor":"Major Extremity Trauma Research Consortium","briefTitle":"Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)","officialTitle":"Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2018-06","completion":"2019-11","firstPosted":"2014-08-28","resultsPosted":"2021-06-01","lastUpdate":"2021-06-01"},"enrollment":1036,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Post Operative Surgical Site Infection"],"interventions":[{"type":"DRUG","name":"Vancomycin antibiotic powder","otherNames":[]}],"arms":[{"label":"Vancomycin Antibotic Powder","type":"EXPERIMENTAL"},{"label":"Standard of Care","type":"NO_INTERVENTION"}],"summary":"The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixation.","primaryOutcome":{"measure":"Number of Clinically Significant Deep Surgical Site Infection (SSI)","timeFrame":"26 weeks","effectByArm":[{"arm":"Vancomycin Antibotic Powder","deltaMin":29,"sd":null},{"arm":"Standard of Care","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33760010"],"seeAlso":["http://metrc.org"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":499},"commonTop":[]}}